ClinicalTrials.gg

Program

palazestrant

Also written as “Palazestrant” and “OP-1250”.

Its studies are mostly in Breast Neoplasms, led by Olema Pharmaceuticals.

Furthest: phase 3, since Aug 17, 20234 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Olema Pharmaceuticals43 open or runningphase 3since Aug 17, 2023Jul 21, 2020Dec 2028phase 3 · NCT07085767

Also a collaborator on its studies: Novartis and Pfizer.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2020First study: phase 2 study in Hormone Receptor Positive Breast CarcinomaFirst studyNCT04505826 · 153 enrolled · United States, Australia
  2. Feb 11, 2022Phase 1 study in Breast NeoplasmsNCT05266105 · 60 enrolled · Australia
  3. Aug 17, 2023Phase 3 study in Breast NeoplasmsNCT06016738 · 510 enrolled · United States, Argentina, Australia and more
  4. Jul 8, 2025Phase 3 study in Breast NeoplasmsNCT07085767 · 1,000 planned · United States, Australia, Austria and more

Ahead

  1. Dec 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07085767

TargetBeta

ESR1 →read by rule
“An orally available, small molecule antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1) and a selective ER degrader (SERD), ”NCIt, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07085767Breast Neoplasms · United States, Australia, Austria and more3RecruitingDec 20281,000
NCT06016738Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingOct 31, 2026510
NCT05266105Breast Neoplasms · Australia1Active, not recruitingMar 202660
NCT04505826Hormone Receptor Positive Breast Carcinoma · United States, Australia2CompletedJul 30, 2024153

How it is read

Names in the registry

  • “Palazestrant”, 3 entries
  • “OP-1250”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.